New program halts population weight gain in Colorado clinics

A novel weight management initiative called PATHWEIGH, developed by endocrinologist Leigh Perreault, has successfully stopped population-level weight gain in primary care settings across Colorado. Tested in a large-scale trial involving over 274,000 patients, the program increased access to obesity treatments and is now attracting interest from health systems nationwide. Published results show a 0.58 kg reduction in average weight gain over 18 months, marking a significant public health advancement.

Endocrinologist Leigh Perreault, a professor at the University of Colorado Anschutz School of Medicine who practices in Westminster, grew frustrated with standard weight management advice in primary care. Patients often left with generic recommendations to eat better and exercise more, despite ongoing issues like diabetes and hypertension. Perreault realized many medications treated symptoms rather than addressing obesity as the root cause. "None of these people want to be on these medications and I thought if I could just help them with their weight, many of these health concerns would probably go away," she said.

To tackle this, Perreault and colleagues created PATHWEIGH, a structured system funded by the National Institutes of Health. It rolled out across 56 UCHealth primary care clinics in Colorado, involving 274,182 patients in one of the largest randomized trials of its kind. The program features dedicated visits focused solely on weight care, triggered by patient requests at the front desk. This activates an electronic health record workflow, including a patient survey that streamlines clinician notes and emphasizes practical steps.

Results, published in Nature Medicine in 2025, revealed PATHWEIGH reduced average population weight gain by 0.58 kg over 18 months, reversing the typical upward trend. It boosted the likelihood of receiving weight-related care by 23%, with one in four eligible patients accessing services like lifestyle counseling. Prescriptions for anti-obesity medications doubled during the trial. "With PATHWEIGH, we showed that we absolutely eliminated population weight gain across all of our primary care, which has never been done previously," Perreault noted.

The approach customizes treatments, reduces awkward weight discussions, and builds a clear pathway for care, likened by Perreault to a "highway" for various weight loss options. While individual changes may seem modest, they hold substantial public health value against annual average gains of about 0.5 kg. The Obesity Association now recommends PATHWEIGH in its standards, and five health systems in seven states are exploring adoption. Perreault calls it a "home-grown" blueprint for advancing obesity care.

ተያያዥ ጽሁፎች

Split-image illustration contrasting swift private clinic access to Mounjaro for the wealthy versus long NHS queues for obesity patients in the UK.
በ AI የተሰራ ምስል

UK researchers warn NHS rollout of Mounjaro could widen inequalities in obesity care

በAI የተዘገበ በ AI የተሰራ ምስል እውነት ተፈትሸ

UK specialists say strict early access rules for the weight-loss drug tirzepatide (Mounjaro) risk creating a “two-tier” obesity treatment system, with people who can pay privately getting faster access than those relying on the National Health Service.

Obesity has surged in South Africa, affecting nearly 11 million adults and costing R33 billion in 2020, equivalent to 16% of government health spending. Despite effective treatments like bariatric surgery and GLP-1 drugs such as Ozempic and Wegovy, medical schemes limit coverage, exacerbating the financial strain on patients and funders. New guidelines aim to reframe obesity as a chronic disease to improve access.

በAI የተዘገበ እውነት ተፈትሸ

Three new Cochrane reviews conclude that tirzepatide, semaglutide and liraglutide produce clinically meaningful weight loss in adults with obesity, while evidence on long‑term safety, broader outcomes and equitable access remains limited. The findings will inform forthcoming World Health Organization guidance on obesity treatment.

Researchers at Karolinska Institutet and Stockholm University have developed an experimental oral drug that boosts metabolism in skeletal muscle, improving blood sugar control and fat burning in early studies without reducing appetite or muscle mass. Unlike GLP-1-based drugs such as Ozempic, the candidate acts directly on muscle tissue and has shown good tolerability in an initial clinical trial, according to the study authors.

በAI የተዘገበ እውነት ተፈትሸ

A secondary analysis of a randomized clinical trial reports that a low-fat vegan diet was associated with greater weight loss than a Mediterranean diet, even when the vegan menu included plant foods such as refined grains and potatoes that are labeled “unhealthful” in a common plant-based diet scoring system. The benefits were linked to replacing animal products with plant foods and limiting added oils and nuts, according to researchers from the Physicians Committee for Responsible Medicine in a study published in Frontiers in Nutrition.

Researchers at the University of Technology Sydney have created experimental compounds that prompt mitochondria to burn more calories safely. These mild mitochondrial uncouplers could offer a new approach to treating obesity without the deadly risks of past chemicals. The findings, published in Chemical Science, highlight potential benefits for metabolic health and aging.

በAI የተዘገበ

Dr. Drew Pinsky appeared on TMZ Live to discuss how weight-loss drugs like Ozempic could have potentially altered the path of Nick Reiner, who murdered his parents amid medication changes. He highlighted the delicate balance of prescribing such drugs alongside anti-psychotics. The insight ties into TMZ's new documentary on the Reiner murders.

 

 

 

ይህ ድረ-ገጽ ኩኪዎችን ይጠቀማል

የእኛን ጣቢያ ለማሻሻል ለትንታኔ ኩኪዎችን እንጠቀማለን። የእኛን የሚስጥር ፖሊሲ አንብቡ የሚስጥር ፖሊሲ ለተጨማሪ መረጃ።
ውድቅ አድርግ